Oncomine MDS Panel – Comprehensive Genetic Testing for Myelodysplastic Syndromes
5.500,00 د.إ
The Oncomine Myelodysplastic Syndrome (MDS) Panel detects genetic mutations linked to MDS and blood cancers. Accurate, next-generation sequencing. Book your test today.
Description
Why You Need This Test
The Oncomine MDS Panel (MDS) Panel is a state-of-the-art next-generation sequencing (NGS) test designed to identify genetic mutations associated with Myelodysplastic Syndromes (MDS) —a group of disorders caused by poorly formed or dysfunctional blood cells in the bone marrow.
MDS can lead to severe anemia, infections, bleeding , and may progress to acute myeloid leukemia (AML) if not diagnosed and managed early. This test analyzes key genes frequently mutated in MDS, including SF3B1 , TET2 , ASXL1 , DNMT3A , RUNX1 , and others, providing critical insights for:
- Confirming MDS diagnosis
- Differentiating MDS from other blood disorders
- Assessing risk of progression to leukemia
- Guiding personalized treatment plans (e.g., hypomethylating agents, stem cell transplant)
- Monitoring response to therapy
This test is especially valuable for patients with unexplained cytopenias, abnormal blood counts, or post-chemotherapy bone marrow changes.
Symptoms That Indicate This Test
You may need the Oncomine MDS Panel if you experience:
- Chronic fatigue or weakness (due to anemia)
- Frequent infections (low white blood cells)
- Easy bruising or bleeding (low platelets)
- Unexplained fever or weight loss
- Abnormal complete blood count (CBC) results
- History of chemotherapy or radiation exposure
- Diagnosis of clonal hematopoiesis (CHIP) or suspected pre-leukemic condition
This test is typically ordered by hematologists or oncologists following a bone marrow biopsy or when standard tests are inconclusive.
Natural Production & Genetic Basis
Myelodysplastic Syndromes arise from acquired mutations in the DNA of bone marrow stem cells. These mutations disrupt normal blood cell production, leading to dysplasia (abnormal cell development) and ineffective hematopoiesis .
The Oncomine MDS Panel uses targeted NGS technology to sequence up to 40+ genes commonly implicated in MDS and related myeloid malignancies. It detects:
- Single nucleotide variants (SNVs)
- Insertions and deletions (Indels)
- Copy number variations (CNVs)
Unlike inherited conditions, these mutations are not present at birth but accumulate over time due to aging, environmental exposures, or prior cancer treatments.
What Happens If Untreated
Without proper diagnosis and management, MDS can lead to:
- Progressive bone marrow failure
- Dependence on blood transfusions
- Increased risk of infections and hemorrhage
- Transformation to Acute Myeloid Leukemia (AML) in 30% of cases
- Reduced quality of life and survival
Early genetic profiling through the Oncomine MDS Panel enables risk stratification and timely intervention—improving outcomes and guiding precision medicine.
Test Overview
| Parameter | Details |
| Test Name | Oncomine Myelodysplastic Syndrome (MDS) Panel |
| Sample Type | Bone Marrow Aspirate or Peripheral Blood (EDTA) |
| Methodology | Next-Generation Sequencing (NGS) |
| Turnaround Time (TAT) | 14–21 Days (standard for complex NGS panels; can be adjusted if confirmed) |
| Genes Analyzed | 40+ genes including “SF3B1 TET2 ASXL1 DNMT3A RUNX1 SRSF2 U2AF1 and more” |
| Reporting | Detailed mutation report with clinical significance and therapeutic implications |
| Category | Molecular Oncology / Hematologic Genetic Testing |
Don’t let uncertainty delay your treatment. The Oncomine Myelodysplastic Syndrome (MDS) Panel offers precision diagnostics for complex blood disorders—helping your doctor deliver the right care at the right time.
👉 Book with Lab Tests Dubai to see if the Oncomine MDS Panel is right for you.
Reviews
There are no reviews yet.